These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32429139)

  • 21. Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer.
    Puhan MA; Yu T; Stegeman I; Varadhan R; Singh S; Boyd CM
    BMC Med; 2015 Oct; 13():250. PubMed ID: 26423305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reevaluating Benefits in the Moral Justification of Animal Research: A Comment on "Necessary Conditions for Morally Responsible Animal Research".
    Eggel M; Neuhaus CP; Grimm H
    Camb Q Healthc Ethics; 2020 Jan; 29(1):131-143. PubMed ID: 31858941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Informing Patient-Centered Care Through Stakeholder Engagement and Highly Stratified Quantitative Benefit-Harm Assessments.
    Aschmann HE; Boyd CM; Robbins CW; Chan WV; Mularski RA; Bennett WL; Sheehan OC; Wilson RF; Bayliss EA; Leff B; Armacost K; Glover C; Maslow K; Mintz S; Puhan MA
    Value Health; 2020 May; 23(5):616-624. PubMed ID: 32389227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the ethical acceptability of animal research.
    Bout HJ; Fentener van Vlissingen JM; Karssing ED
    Lab Anim (NY); 2014 Nov; 43(11):411-4. PubMed ID: 25333594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of reproductive toxicity and classification of glufosinate-ammonium.
    Schulte-Hermann R; Wogan GN; Berry C; Brown NA; Czeizel A; Giavini E; Holmes LB; Kroes R; Nau H; Neubert D; Oesch F; Ott T; Pelkonen O; Robert-Gnansia E; Sullivan FM
    Regul Toxicol Pharmacol; 2006 Apr; 44(3 Suppl 1):S1-76. PubMed ID: 16510221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Researching health inequalities with Community Researchers: practical, methodological and ethical challenges of an 'inclusive' research approach.
    Salway S; Chowbey P; Such E; Ferguson B
    Res Involv Engagem; 2015; 1():9. PubMed ID: 29062498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing ethics and animal welfare in animal biotechnology for farm production.
    Kaiser M
    Rev Sci Tech; 2005 Apr; 24(1):75-87. PubMed ID: 16110878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
    Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
    Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to develop cost-conscious guidelines.
    Eccles M; Mason J
    Health Technol Assess; 2001; 5(16):1-69. PubMed ID: 11427188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD.
    Puhan MA; Yu T; Boyd CM; Ter Riet G
    BMC Med; 2015 Jul; 13():157. PubMed ID: 26137986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using a patient-centered approach to benefit-harm assessment in treatment decision-making: a case study in uveitis.
    Yu T; Holbrook JT; Thorne JE; Puhan MA
    Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):363-71. PubMed ID: 26798977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically modified animals from life-science, socio-economic and ethical perspectives: examining issues in an EU policy context.
    Frewer LJ; Kleter GA; Brennan M; Coles D; Fischer AR; Houdebine LM; Mora C; Millar K; Salter B
    N Biotechnol; 2013 Jun; 30(5):447-60. PubMed ID: 23567982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethical arguments relevant to the use of GM crops.
    Weale A
    N Biotechnol; 2010 Nov; 27(5):582-7. PubMed ID: 20850572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A national public health programme on gambling policy development in New Zealand: insights from a process evaluation.
    Kolandai-Matchett K; Landon J; Bellringer M; Abbott M
    Harm Reduct J; 2018 Mar; 15(1):11. PubMed ID: 29510708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating benefits and harm of therapies.
    Faggion CM
    J Evid Based Dent Pract; 2016 Sep; 16(3):147-153. PubMed ID: 27855829
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.